Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: June 22, 2017
What are the generic sources for reserpine and what is the scope of reserpine freedom to operate?
Reserpine is the generic ingredient in thirteen branded drugs marketed by Watson Labs, Tablicaps, Lilly, Novartis, Pvt Form, Teva, Barr, Whiteworth Town Plsn, Lannett, Mk Labs, Impax Labs, Bowman Pharms, Rexall, Sandoz, Everylife, Elkins Sinn, Vitarine, Solvay, Purepac Pharm, Vale, Bristol Myers Squibb, Halsey, Bell Pharma, Cycle Pharms Ltd, Bundy, Pharmavite, Valeant Pharm Intl, Mylan, Hikma Intl Pharms, Ivax Sub Teva Pharms, Panray, Marshall Pharma, Schering, and Sanofi Aventis Us, and is included in forty-three NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.| Tradenames: | 13 |
| Patents: | 1 |
| Applicants: | 34 |
| NDAs: | 43 |
| Drug Master File Entries: see list | 19 |
| Bulk Api Vendors: see list | 47 |
| Clinical Trials: see list | 12 |
| Patent Applications: see list | 6,610 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see low prices |
| DailyMed Link: | reserpine at DailyMed |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bowman Pharms | HISERPIA | reserpine | TABLET;ORAL | 009631-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Teva | RESERPINE | reserpine | TABLET;ORAL | 089020-001 | Mar 7, 1985 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Bristol Myers Squibb | RAU-SED | reserpine | TABLET;ORAL | 009357-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Lannett | SERPALAN | reserpine | TABLET;ORAL | 010124-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
Purepac Pharm | RESERPINE | reserpine | TABLET;ORAL | 080753-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ► Subscribe | ► Subscribe | |||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639
Follow DrugPatentWatch:
Join the 21,660 other biopharmaceutical professionals who get our Drug Patent Expiration Alerts:
